Filip Rega,Guillaume Lebreton,Marylou Para,Sebastian Michel,René Schramm,Emmanuelle Begot,Katrien Vandendriessche,Christine Kamla,Gino Gerosa,Marius Berman,Udo Boeken,Steven Clark,Aaron Ranasinghe,Fabio Ius,Alberta Forteza,Aldina Pivodic,Felix Hennig,Sabina Guenther,Andreas Zuckermann,Christoph Knosalla,Göran Dellgren,Andreas Wallinder,NIHP2019 investigators,Johan Van Cleemput,Karlien Degezelle,Leonhard Wert,Ruhi Yeter,Artur Lichtenber,Hug Aubin,Adelheid Görler,Susanne Freyt,Adam McDiamud,Jerome Jungschleger,Majid Mukadam,Paul Turner,Rebecca Mullen,Francisco Hernández,Victor Ospina,Kristjan Jonsson,Lisa Ternström,Hamed Al Kalbany,Nima Djavidi,Assunta Fabozzo,Nicola Pradegan,Arezu Aliabadi-Zuckermann,Emilio Osorio

Abstract:Background: Static cold storage (SCS) remains the gold standard for preserving donor hearts before transplantation but is associated with ischaemia, anaerobic metabolism, and organ injuries, leading to patient morbidity and mortality. We aimed to evaluate whether continuous, hypothermic oxygenated machine perfusion (HOPE) of the donor heart is safe and superior compared with SCS. Methods: We performed a multinational, multicentre, randomised, controlled, open-label clinical trial with a superiority design at 15 transplant centres across eight European countries. Adult candidates for heart transplantation were eligible and randomly assigned in a 1:1 ratio. Donor inclusion criteria were age 18-70 years with no previous sternotomy and donation after brain death. In the treatment group, the preservation protocol involved the use of a portable machine perfusion system ensuring HOPE of the resting donor heart. The donor hearts in the control group underwent ischaemic SCS according to standard practices. The primary outcome was time to first event of a composite of either cardiac-related death, moderate or severe primary graft dysfunction (PGD) of the left ventricle, PGD of the right ventricle, acute cellular rejection at least grade 2R, or graft failure (with use of mechanical circulatory support or re-transplantation) within 30 days after transplantation. We included all patients who were randomly assigned, fulfilled inclusion and exclusion criteria, and received a transplant in the primary analysis and all patients who were randomly assigned and received a transplant in the safety analyses. This trial was registered with ClicalTrials.gov (NCT03991923) and is ongoing. Findings: A total of 229 patients were enrolled between Nov 25, 2020, and May 19, 2023. The primary analysis population included 204 patients who received a transplant. There were no patients who received a transplant lost to follow-up. All 100 donor hearts preserved with HOPE were transplantable after perfusion. The primary endpoint was registered in 19 (19%) of 101 patients in the HOPE group and 31 (30%) of 103 patients in the SCS group, corresponding to a risk reduction of 44% (hazard ratio 0·56; 95% CI 0·32-0·99; log-rank test p=0·059). PGD was the primary outcome event in 11 (11%) patients in the HOPE group and 29 (28%) in the SCS group (risk ratio 0·39; 95% CI 0·20-0·73). In the HOPE group, 63 (65%) patients had a reported serious adverse event (158 events) versus 87 (70%; 222 events) in the SCS group. Major adverse cardiac transplant events were reported in 18 (18%) and 33 (32%) patients in the HOPE and SCS group (risk ratio 0·56; 95% CI 0·34-0·92). Interpretation: Although there was not a significant difference in the primary endpoint, the 44% risk reduction associated with HOPE was suggested to be a clinically meaningful benefit. Post-transplant complications, measured as major adverse cardiac transplant events, were reduced. Analysis of secondary outcomes suggested that HOPE was beneficial in reducing primary graft dysfunction. HOPE in donor heart preservation addresses the existing challenges associated with graft preservation and the increasing complexity of donors and heart transplantation recipients. Future investigation will help to further elucidate the benefit of HOPE. Funding: XVIVO Perfusion.

Oxygenated versus non-oxygenated flush out during deceased donor liver procurement: The first proof-of-concept study in humans

An oxygenated perfluorocarbon emulsion improves liver graft preservation evaluated in DCD livers of male sprague dawley rats

Assessment of liver graft quality during hypothermic oxygenated perfusion: the first international validation study

Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial

Evaluating the Performance of a Nonelectronic, Versatile Oxygenating Perfusion System across Viscosities Representative of Clinical Perfusion Solutions Used for Organ Preservation

A randomized trial of normothermic preservation in liver transplantation

Application of a novel artificial perfusate based on oxygen-carrying nanoparticles in normothermic machine perfusion for porcine liver preservation after cardiac death

Impact of human-derived hemoglobin based oxygen vesicles as a machine perfusion solution for liver donation after cardiac death in a pig model

Hypothermic oxygenated machine perfusion influences the immunogenicity of donor livers in humans

Defatting of donor transplant livers during normothermic perfusion—a randomised clinical trial: study protocol for the DeFat study

Preclinical validation of a customized circuit for ex situ uninterrupted cold‐to‐warm prolonged perfusion of the liver

Implementation and design of customized ex vivo machine perfusion. Analysis of its first results

A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease

Cold flush after dynamic liver preservation protects against ischemic changes upon reperfusion - an experimental study

Efficiency of machine perfusion in pediatric liver transplantation

Hypothermic oxygenated perfusion in liver transplantation: a meta-analysis of randomized controlled trials and matched studies

Perioperative fluid management and outcomes in adult deceased donor liver transplantation - A systematic review of the literature and expert panel recommendations

Normothermic Machine Perfusion (NMP) of the Liver as a Platform for Therapeutic Interventions during Ex-Vivo Liver Preservation: A Review

End-ischemic pharmacological cocktail treatment to mitigate rewarming/reperfusion injury

Ischemia-Free Liver Transplant: Technical Aspects and Considerations After First Case in Western Countries

Evaluation of the efficacy of HEMO2life®, a marine OXYgen carrier for Organ Preservation (OxyOp2) in renal transplantation: study protocol for a multicenter randomized trial